CereVasc's Minimally Invasive Central Nervous System Therapy Delivery System Receives Outstanding Presentation Award at American Society of Gene & Cell Therapy Annual Meeting
BOSTON, June 14, 2023 /PRNewswire/ -- CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel treatments for neurological diseases, announced today that a presentation of study results for its minimally invasive Central Nervous System (CNS) Delivery System was awarded an Outstanding Poster Presentation Award by the American Society of Gene and Cell Therapy as part of their 2023 Annual Meeting.
- BOSTON, June 14, 2023 /PRNewswire/ -- CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel treatments for neurological diseases, announced today that a presentation of study results for its minimally invasive Central Nervous System (CNS) Delivery System was awarded an Outstanding Poster Presentation Award by the American Society of Gene and Cell Therapy as part of their 2023 Annual Meeting.
- "We are honored that ASGCT recognized data on our minimally invasive CNS Delivery System with an Outstanding Poster Presentation Award," said Dan Levangie, Chairman and CEO of CereVasc.
- "We appreciate the challenges faced by CNS therapeutic researchers and industry to identify an effective and minimally invasive route of administration for their therapeutic assets.
- We believe our data highlighted with this Award demonstrates the potential of our novel alternative to more invasive techniques employed to deliver therapies to the CNS.